1.2 Venipuncture, Vascular Access & Emergency Response

1.2 Venipuncture, Vascular Access & Emergency Response

Venipuncture and Vein Selection

The administration of radiopharmaceuticals requires mastery of venipuncture and vascular access. Unlike standard phlebotomy, which simply withdraws blood, nuclear medicine venipuncture establishes a route for the delivery of radioactive materials, demanding precise technique to avoid complications like extravasation.

Site Selection: The selection of an appropriate vein is a critical first step. The ideal vein is straight, bouncy, and free of valves or sclerosis.

• Primary Choice: The median cubital vein, located in the antecubital fossa, is generally the preferred site due to its large size, superficial location, and stability.
• Secondary Choices: The cephalic and basilic veins in the forearm or antecubital space.
• Alternative Sites: Veins in the dorsum of the hand may be used if antecubital access is impossible, but they are more fragile, prone to rolling, and more painful for the patient.
• Sites to Avoid: Technologists must never attempt venipuncture in an arm on the side of a previous mastectomy (due to the risk of lymphedema), in an arm with a functioning dialysis fistula or graft, or in limbs with massive edema, burns, or scarring.

Venipuncture Technique:

1. Apply the tourniquet 3-4 inches above the intended insertion site to engorge the vein.
2. Cleanse the site with an alcohol swab using an outward concentric motion and allow it to dry completely.
3. Anchor the vein by pulling the skin taut below the site.
4. Insert the needle (typically a 20 to 22-gauge butterfly needle or straight IV catheter) at a 15-30 degree angle with the bevel facing up.
5. Observe for a "flash" of blood in the tubing, indicating successful venous entry.
6. Release the tourniquet before injecting the radiopharmaceutical to prevent excessive backpressure that could lead to extravasation.
7. Flush the line with normal saline before and immediately after the injection to ensure the entire dose is delivered and the vein remains patent.

Management of Extravasation

Extravasation (or infiltration) occurs when the radiopharmaceutical leaks out of the vein and into the surrounding subcutaneous tissue. In nuclear medicine, this is a significant event. Not only does it reduce the circulating dose (potentially rendering the scan non-diagnostic or requiring a repeat study), but depending on the isotope, it can deliver a high localized radiation dose to the tissue.

Signs of Extravasation:

• Swelling or a visible bleb at the injection site.
• Patient complaints of burning, stinging, or pain during the injection.
• Resistance felt on the syringe plunger.
• Lack of a blood return upon aspiration.

Immediate Management: If extravasation is suspected, the technologist must immediately STOP the injection. The needle should be withdrawn, and firm pressure applied to the site. Depending on institutional policy and the specific radiopharmaceutical, management may involve applying a warm or cold compress and elevating the affected extremity to promote lymphatic drainage and dispersion of the tracer. The event must be thoroughly documented, and the reading physician and Radiation Safety Officer (RSO) must be notified, as calculations of the localized radiation dose may be required.

Maintenance of IV Lines

Many nuclear medicine patients arrive with existing intravenous access. Technologists must know how to safely utilize and maintain these lines.

• Always verify the patency of an existing IV by aspirating for blood and flushing with normal saline before injecting any radiopharmaceutical.
• Never administer radiopharmaceuticals into lines designated for total parenteral nutrition (TPN), patient-controlled analgesia (PCA) pumps, or dedicated arterial lines.
• Central venous catheters (e.g., PICC lines, Hickman catheters) can sometimes be used, but strict aseptic technique must be followed, and institutional protocols regarding which personnel are authorized to access them must be strictly adhered to.

Adverse Reactions and Emergency Response

While true allergic reactions to pure radiopharmaceuticals are exceedingly rare (due to the minute, tracer-level mass of the injected chemical), reactions to adjunct medications (like pharmacological stress agents, contrast media, or interventional drugs) are a real and ever-present danger. Technologists must be prepared to act decisively.

Mild to Moderate Reactions: Symptoms may include nausea, vomiting, localized urticaria (hives), or mild bronchospasm. Management involves reassuring the patient, monitoring vital signs, and potentially administering antihistamines (e.g., diphenhydramine) as ordered by a physician.

Severe Reactions (Anaphylaxis): Anaphylaxis is a severe, life-threatening systemic allergic reaction. Symptoms escalate rapidly and include severe respiratory distress (laryngeal edema, wheezing), profound hypotension, tachycardia, and loss of consciousness.

• First-Line Treatment: The immediate, primary treatment for anaphylaxis is the intramuscular (IM) injection of Epinephrine. The standard adult dose is 0.3 to 0.5 mg (often delivered via an auto-injector like an EpiPen) injected into the anterolateral thigh.
• Subsequent treatments may include supplemental oxygen, IV fluids for hypotension, and corticosteroids.
• The technologist must immediately call for emergency medical assistance (e.g., calling a "Code Blue") while initiating first aid.

Cardiac Arrest Protocols

In the event a patient becomes unresponsive and loses a palpable pulse, the technologist must immediately activate the emergency response system and initiate Basic Life Support (BLS).

• Assess responsiveness and breathing.
• Call for help and ask someone to bring the automated external defibrillator (AED) and the crash cart.
• Begin high-quality chest compressions immediately (at a rate of 100-120 compressions per minute, at a depth of at least 2 inches).
• Follow the prompts of the AED as soon as it arrives. Nuclear medicine technologists must maintain current CPR/BLS certification and be intimately familiar with the location and contents of the department's emergency crash cart.